Abstract
There is a current high demand for nontypable Haemophilus influenzae (NTHi) vaccines. Various options for the composition of such vaccines are possible. Decisions about the vaccine composition have to take into account the antigenic variability of NTHi, so even complex immunogens such as whole bacteria would preferentially have a tailor-made antigenic composition. We will present a summary of NTHi vaccine development, describing research efforts from SmithKline Beecham and other laboratories. Currently, major (P1, P2, P4, P5) and minor (P6, D15, TbpA/B, ellipsis) outer membrane proteins, LPS, adhesins (HMW, Hia, pili, P5) are being studied. Preclinical results with LPD, P5 (LB1) and OMP26 from our laboratories will be described including the use of animal models of otitis and lung infection.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Amino Acid Sequence
-
Animals
-
Antigens, Bacterial / immunology
-
Apolipoproteins / immunology
-
Apolipoproteins / isolation & purification
-
Apolipoproteins D
-
Bacterial Outer Membrane Proteins / immunology
-
Bacterial Outer Membrane Proteins / isolation & purification
-
Bacterial Typing Techniques
-
Chinchilla
-
Haemophilus Infections / immunology
-
Haemophilus Infections / microbiology
-
Haemophilus Infections / prevention & control
-
Haemophilus Vaccines / immunology*
-
Haemophilus influenzae / classification
-
Haemophilus influenzae / immunology*
-
Humans
-
Molecular Sequence Data
-
Nasopharynx / immunology
-
Otitis Media / immunology
-
Otitis Media / microbiology
-
Otitis Media / prevention & control
-
Rats
-
Vaccination
Substances
-
Antigens, Bacterial
-
Apolipoproteins
-
Apolipoproteins D
-
Bacterial Outer Membrane Proteins
-
Haemophilus Vaccines
-
OMP26 protein, Haemophilus influenzae
-
outer membrane protein P5, Haemophilus